{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:53:43Z","timestamp":1781618023770,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Investigaci\u00f3n Cl\u00ednica"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ric.2026.100043","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:40:19Z","timestamp":1780317619000},"page":"100043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in patients with psoriasis: An updated systematic review and meta-analysis"],"prefix":"10.1016","volume":"78","author":[{"given":"Hongwei","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ric.2026.100043_bib0225","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ric.2026.100043_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events","volume":"77","author":"Egeberg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0235","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks","volume":"139","author":"Von Stebut","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0240","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ric.2026.100043_bib0245","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1097\/HEP.0000000000000696","article-title":"Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ric.2026.100043_bib0250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ric.2026.100043_bib0255","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ric.2026.100043_bib0260","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1111\/ajd.13098","article-title":"Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk","volume":"60","author":"Romero-P\u00e9rez","year":"2019","journal-title":"Austr J Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0265","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3390\/ijms25052660","article-title":"Intersecting pathways: nonalcoholic fatty liver disease and psoriasis duet \u2013 a comprehensive review","volume":"25","author":"Costache","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ric.2026.100043_bib0270","first-page":"503","article-title":"Psoriasis and non-alcoholic fatty liver disease","volume":"19","author":"Sch\u00f6n","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ric.2026.100043_bib0275","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/jdv.13456","article-title":"Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis","volume":"30","author":"Gisondi","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ric.2026.100043_bib0280","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00535-013-0768-3","article-title":"Insulin-related biomarkers and their relationship with hepatic fibrosis risk in patients with psoriasis, metabolic syndrome and non-alcoholic fatty liver disease","volume":"48","author":"Kawada","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ric.2026.100043_bib0285","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bjd.16239","article-title":"Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?","volume":"179","author":"Prussick","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155405","article-title":"Nutrition and psoriasis","volume":"21","author":"Kanda","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ric.2026.100043_bib0295","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.ric.2026.100043_bib0300","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ric.2026.100043_bib0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.10.046","article-title":"Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease","volume":"19","author":"Wong","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ric.2026.100043_bib0310","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","article-title":"Should we undertake surveillance for HCC in patients with NAFLD?","volume":"68","author":"Younes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ric.2026.100043_bib0315","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ric.2026.100043_bib0320","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.ric.2026.100043_bib0325","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12016-024-08995-3","article-title":"Atopic dermatitis and psoriasis: similarities and differences in metabolism and microbiome","volume":"66","author":"Chen","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ric.2026.100043_bib0330","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ric.2026.100043_bib0335","article-title":"The essential role of IL-17 as the pathogenetic link between psoriasis and metabolic-associated fatty liver disease","volume":"13","author":"Olveira","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ric.2026.100043_bib0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512483","article-title":"IL-23\/IL-17 axis in chronic hepatitis c and non-alcoholic steatohepatitis-new insight into immunohepatotoxicity of different chronic liver diseases","volume":"24","author":"Vujovic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ric.2026.100043_bib0345","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0355","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1430586","article-title":"Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions","volume":"14","author":"Zou","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ric.2026.100043_bib0360","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00403-024-03625-6","article-title":"Psoriasis treatments in the stabilization of atherosclerosis: a systematic review","volume":"317","author":"Ji","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ric.2026.100043_bib0365","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ric.2026.100043_bib0370","article-title":"TNF-\u03b1 antagonizes the effect of leptin on insulin secretion through FOXO1-dependent transcriptional suppression of LepRb in INS-1 cells","volume":"2022","author":"Zhang","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.ric.2026.100043_bib0375","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/VHRM.S464471","article-title":"Cardiovascular considerations and implications for treatment in psoriasis: an updated review","volume":"20","author":"Mehta","year":"2024","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.ric.2026.100043_bib0380","first-page":"33","article-title":"A case-control study to evaluate the prevalence of nonalcoholic fatty liver disease among patients with moderate-to-severe psoriasis","volume":"11","author":"Awosika","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0385","first-page":"e57487","article-title":"Non-alcoholic fatty liver disease among Iraqi patients with psoriasis: a case\u2013control study","volume":"16","author":"Dhaher","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ric.2026.100043_bib0390","article-title":"Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case\u2013control study and serological comparison","volume":"11","author":"Lin","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ric.2026.100043_bib0395","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-0960.2012.00905.x","article-title":"The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India","volume":"53","author":"Madanagobalane","year":"2012","journal-title":"Austr J Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0400","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4103\/ijd.ijd_1015_22","article-title":"Interleukin levels and non-alcoholic fatty liver disease in chronic plaque psoriasis: an analytical case control study[J]","volume":"68","author":"Yadav","year":"2023","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0405","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.ric.2026.100043_bib0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840106","article-title":"Bidirectional association between psoriasis and nonalcoholic fatty liver disease: real-world evidence from two longitudinal cohort studies","volume":"13","author":"Gau","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ric.2026.100043_bib0415","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/jamadermatol.2017.5417","article-title":"Association of psoriasis with comorbidity development in children with psoriasis","volume":"154","author":"Tollefson","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0420","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study","volume":"70","author":"Van der Voort","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0425","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/ced.12672","article-title":"Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease","volume":"40","author":"Abedini","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0430","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jceh.2021.11.016","article-title":"The association between chronic plaque psoriasis and nonalcoholic fatty liver disease in Indian patients: results of a pilot study","volume":"12","author":"Mahajan","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.ric.2026.100043_bib0435","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamadermatol.2022.1609","article-title":"Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults","volume":"158","author":"Ruan","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ric.2026.100043_bib0440","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ced\/llac028","article-title":"Cross-sectional study to estimate the prevalence and risk factors of nonalcoholic fatty liver disease in children and adolescents with psoriasis","volume":"48","author":"Panjiyar","year":"2023","journal-title":"Clin Exp Dermatol"}],"container-title":["Revista de Investigaci\u00f3n Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034837626000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034837626000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:04:55Z","timestamp":1781615095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034837626000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0034837626000100"],"URL":"https:\/\/doi.org\/10.1016\/j.ric.2026.100043","relation":{},"ISSN":["0034-8376"],"issn-type":[{"value":"0034-8376","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in patients with psoriasis: An updated systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Revista de Investigaci\u00f3n Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ric.2026.100043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubiran.","name":"copyright","label":"Copyright"}],"article-number":"100043"}}